文献速递眼底病与葡萄膜炎

地塞米松植入联合导航阈下微脉冲黄激光治疗糖尿病黄斑水肿的疗效

EFFICACY OF COMBINED DEXAMETHASONE IMPLANT AND NAVIGATED SUBTHRESHOLD MICROPULSE YELLOW LASER IN DIABETIC MACULAR EDEMA.
PubMed 文献 · Retina · 2026-01-01

这项前瞻性随机研究纳入80只中心受累型糖尿病黄斑水肿眼,比较地塞米松植入后4周联合导航阈下微脉冲黄激光与地塞米松单药治疗的疗效。联合组在6个月和12个月的最佳矫正视力改善及黄斑中心凹厚度均优于单药组,且无额外安全性问题。

要点

  • 联合组6个月视力改善6.2±5.1 letters,优于单药组4.1±6.4 letters(P=0.03)。
  • 联合组6个月黄斑中心凹厚度295±46 µm,低于单药组321±58 µm(P=0.02)。
  • 联合组中位无再注射生存期11.2个月,长于单药组8.3个月。

核心结论

  • 地塞米松植入后4周序贯导航阈下微脉冲黄激光可改善糖尿病黄斑水肿的视力和解剖结局,并延长无再注射间期,无额外安全性顾虑。

研究设计与样本

  • 前瞻性随机研究,纳入80只中心受累型糖尿病黄斑水肿眼,联合组40眼接受地塞米松植入后4周导航阈下微脉冲黄激光,单药组40眼仅接受地塞米松植入。

主要发现

  • 6个月时联合组最佳矫正视力改善6.2±5.1 letters,单药组4.1±6.4 letters(P=0.03)。
  • 12个月时联合组最佳矫正视力改善5.8±6.5 letters,单药组3.6±6.8 letters(P=0.05)。
  • 6个月时联合组黄斑中心凹厚度295±46 µm,单药组321±58 µm(P=0.02)。
  • 12个月时联合组黄斑中心凹厚度315±60 µm,单药组342±70 µm(P=0.05)。
  • 联合组中位无再注射生存期11.2个月,单药组8.3个月。

临床怎么用

  • 对中心受累型糖尿病黄斑水肿,可在地塞米松植入后4周序贯导航阈下微脉冲黄激光以改善视力和解剖结局并延长再注射间期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare functional and anatomical outcomes of combining intravitreal dexamethasone implant (DEX-I) (Ozurdex) with navigated subthreshold yellow (577 nm) micropulse laser (subthreshold micropulse laser treatment [SMLT]) versus dexamethasone monotherapy in diabetic macular edema. METHODS: In this prospective randomized study, 80 eyes with center-involving diabetic macular edema were allocated to two groups: 40 eyes received DEX-I followed 4 weeks later by navigated SMLT (DEX-I + SMLT), and 40 eyes received DEX-I alone (DEX-I). Best-corrected visual acuity (Early Treatment Diabetic Retinopathy Study - ETDRS letters), central subfield thickness, and ETDRS subfield thicknesses were measured at baseline and at 2, 4, 6, 9, and 12 months. Reinjection-free survival was analyzed over 12 months. RESULTS: At 6 months, mean best-corrected visual acuity improvement was greater in the DEX-I + SMLT group than in the DEX-I monotherapy group (6.2 ± 5.1 vs. 4.1 ± 6.4 letters; P = 0.03), and this difference persisted at 12 months (5.8 ± 6.5 vs. 3.6 ± 6.8 letters; P = 0.05). Mean central subfield thickness was lower in the DEX-I + SMLT group at 6 months (295 ± 46 vs. 321 ± 58 µ m; P = 0.02) and remained lower at 12 months (315 ± 60 vs. 342 ± 70 µ m; P = 0.05). Median retreatment-free survival was longer in the combination group (11.2 vs. 8.3 months). CONCLUSION: Within the 12-month follow-up period, sequential navigated SMLT performed 4 weeks after dexamethasone implantation was associated with improvements in visual and anatomical outcomes and with a longer retreatment-free interval compared with dexamethasone monotherapy, without additional safety concerns.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Oliverio GW, Meduri A, Ingrande I, et al. EFFICACY OF COMBINED DEXAMETHASONE IMPLANT AND NAVIGATED SUBTHRESHOLD MICROPULSE YELLOW LASER IN DIABETIC MACULAR EDEMA. Retina. 2026. PMID: 41875416. doi:10.1097/IAE.0000000000004843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。